Can-Fite BioPharma Ltd. (CANF)
$1.95+0.00%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2M
- Beta
- 0.02
- P/E (TTM)
- -0.28
- Short % float
- 6.85%
- Days to cover
- 1.2
- SI change
- -6.3%
- 1W
- -8.88%
- 1M
- -15.22%
- vs SPY 1W
- -8.74%
- vs SPY 1M
- -17.72%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 23
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-109.7%
REV YoY-
ROE-182.9%
EPS YoY-
ROA-118.6%
GROSS100
OP-2403
NET-2359
[VALUATION]
P/E TTM-0.28
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.76
P/FCF-
EV/EBITDA-0.14
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.01
ALTMAN Z-
CURR RATIO3.60
ND/EBITDA-
BETA0.02
Company news
FAQ
- What is LOPJLB’s current signal on CANF?
- LOPJLB’s latest quantitative signal on Can-Fite BioPharma Ltd. (CANF) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CANF in?
- Can-Fite BioPharma Ltd. (CANF) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Can-Fite BioPharma Ltd. (CANF) do?
- Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and co…